Armata Pharmaceuticals Business Summary

Armata Pharmaceuticals, Inc. (ARMP) is a late clinical-stage biotechnology company specializing in the development of pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant bacterial infections. The company generates revenue primarily through strategic research collaborations, such as its partnership with Merck to develop synthetic phage candidates, and non-dilutive funding from government and non-profit grants, including the U.S. Department of Defense and the Cystic Fibrosis Foundation. Armata operates through a single business segment focused on its proprietary phage-based technology platform, which supports a pipeline led by AP-SA02 for Staphylococcus aureus and AP-PA02 for Pseudomonas aeruginosa. In the competitive landscape, Armata contends with firms like BiomX, Spero Therapeutics, and Nabriva Therapeutics; however, it distinguishes itself as a market leader by being the first to advance a bacteriophage candidate into a pivotal Phase 3 superiority study, supported by its in-house cGMP manufacturing facility in Los Angeles. Formed in May 2019 through the merger of C3J Therapeutics and AmpliPhi Biosciences, Armata is led by Chief Executive Officer Deborah Birx, M.D., a world-renowned medical expert and former response coordinator for the White House Coronavirus Task Force. The executive team includes David House, who serves as Senior Vice President of Finance and Principal Financial Officer, and Pierre Kyme, Ph.D., the Chief Business Officer who previously led product development at C3J. The company is heavily backed by Innoviva, Inc., which holds a majority stake of approximately 69%, and its board of directors features prominent industry figures such as Chair Robin C. Kramer, the CFO of Biogen, and Odysseas Kostas, M.D., a Partner at Sarissa Capital Management. This leadership pedigree combines deep regulatory expertise with significant institutional support to navigate the complex path toward the commercialization of phage therapy.